Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2576010 | 0.79 | LMNA (0.50) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL8654643 | 0.78 | ALDH1A1 (0.49) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL8653231 | 0.78 | ALDH1A1 (0.49) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL8654462 | 0.78 | ALDH1A1 (0.49) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL8652188 | 0.74 | ALDH1A1 (0.51) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL8655261 | 0.67 | ALDH1A1 (0.65) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL7379538 | 0.67 | SMN1; SMN2 (0.56) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL8521929 | 0.66 | ALDH1A1 (0.50) | ALDH1A1LMNATP53HPGDTSHR | |
| SCHEMBL7845674 | 0.65 | FFAR3 (0.64) | ALDH1A1TP53HPGDTSHRHSD17B10 | |
| SCHEMBL7148358 | 0.63 | ALDH1A1 (0.58) | ALDH1A1LMNATP53HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315497-B2 | Tricyclic and tetracyclic systems with activity on the central nervous and vascular systems | Centro de Investigacion Y Desarrollo de . . . (CIDEM) Laboratorio de Sintesis Organica de La Facultad . . . (CU) | 2016-04-19 | — | — | US | disclosed |
| US-20120202791-A1 | Tricyclic and Tetracyclic Systems with Activity on the Central Nervous and Vascular Systems | CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS (CIDEM) (CU) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202791-A1 | Tricyclic and Tetracyclic Systems with Activity on the Central Nervous and Vascular Systems | CACNA1I, CACNA1G, CACNA1D | ALDH1A1 1048/4885LMNA 3002/4885TP53 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.